Clinical Trial: Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Comparison With Controls and Effect of Rectal Ozone. (MicrOzoGineTox).

U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07259681) titled 'Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Comparison With Controls and Effect of Rectal Ozone. (MicrOzoGineTox).' on Nov. 21.

Brief Summary: Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of...